Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease.

In view of the apparent controversial properties of (-)-nicotine (NIC) in relation to both oxidative stress and neuroprotection, we studied the effects of NIC on hydroxyl radical (*OH) formation, oxidative stress production by 6-hydroxydopamine (6-OHDA) autoxidation in the presence and absence of ascorbate, and 6-OHDA neurotoxicity. Both NIC and (-)-cotinine (COT) exhibited increased *OH production during 6-OHDA autoxidation. Although the same effect was observed in *OH generation by the Fenton reaction (H2O2 + Fe2+), this reaction was completely prevented with the previous incubation of Fe2+ with NIC or COT. Furthermore, both NIC and COT demonstrated a capacity to be able to reduce the TBARS formation provoked in rat brain mitochondrial preparations by 6-OHDA autoxidation. This effect is assumed as a consequence of the action of NIC and COT on lipid peroxidation propagation. We treated with NIC (1mg/kg, i.p.) two 6-OHDA-induced rat models of Parkinson's disease. However, only in one of these models did we obtain clear evidence of a neuroprotective effect of NIC on nigrostriatal terminals, as revealed by immunohistochemistry against tyrosine hydroxylase. Thus, the antioxidant properties of both NIC and COT in relation to the lipid peroxidation induced by 6-OHDA autoxidation, together with their reported capacity to prevent the Fenton reaction, probably by sequestration of Fe2+, may contribute to an understanding of its neuroprotective properties. In addition, the reported capacity of both NIC and COT to increase the production of *OH by 6-OHDA autoxidation might help explain the controversial observation found under different experimental conditions.

[1]  J. Drago,et al.  Dose‐related neuroprotective effects of chronic nicotine in 6‐hydroxydopamine treated rats, and loss of neuroprotection in α4 nicotinic receptor subunit knockout mice , 2001, British journal of pharmacology.

[2]  A. Stern,et al.  Effects of superoxide dismutase and catalase on catalysis of 6-hydroxydopamine and 6-aminodopamine autoxidation by iron and ascorbate. , 1981, Biochemical pharmacology.

[3]  A. Davison,et al.  Interactions between metals, ligands, and oxygen in the autoxidation of 6-hydroxydopamine: mechanisms by which metal chelation enhances inhibition by superoxide dismutase. , 1987, Archives of biochemistry and biophysics.

[4]  S. Mandel,et al.  The Pivotal Role of Iron in NF‐κB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators , 1999, Annals of the New York Academy of Sciences.

[5]  D. Ben-shachar,et al.  The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons , 1991, Journal of neurochemistry.

[6]  A. K. Agarwal,et al.  Free Radical‐Generated Neurotoxicity of 6‐Hydroxydopamine , 1995, Journal of neurochemistry.

[7]  J. Labandeira-Garcia,et al.  Autoxidation and Neurotoxicity of 6‐Hydroxydopamine in the Presence of Some Antioxidants , 2000, Journal of neurochemistry.

[8]  K. Jellinger,et al.  Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.

[9]  Robert Eisenthal,et al.  Enzyme assays : a practical approach , 1992 .

[10]  N. Tolbert,et al.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. , 1978, Analytical biochemistry.

[11]  I. Afanas’ev,et al.  Mechanism of inhibitory effects of chelating drugs on lipid peroxidation in rat brain homogenates. , 1994, Biochemical pharmacology.

[12]  I. Liste,et al.  Time course of striatal changes induced by 6-hydroxydopamine lesion of the nigrostriatal pathway, as studied by combined evaluation of rotational behaviour and striatal Fos expression , 1996, Experimental Brain Research.

[13]  K. Tipton,et al.  Nature of Inhibition of Mitochondrial Respiratory Complex I by 6‐Hydroxydopamine , 1996, Journal of neurochemistry.

[14]  F. Speizer,et al.  Cigarette smoking and the incidence of Parkinson's disease in two prospective studies , 2001, Annals of neurology.

[15]  Y. Agid,et al.  Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.

[16]  G Becker,et al.  Iron accumulation in the substantia nigra in rats visualized by ultrasound. , 1999, Ultrasound in medicine & biology.

[17]  T. Loh.  THE EFFECTS OF DERANGEMENT OF CELL MEMBRANE STRUCTURE AND INHIBITORS ON TRANSFERRIN AND IRON UPTAKE BY RETICULOCYTES , 1982, Clinical and experimental pharmacology & physiology.

[18]  Barry Halliwell,et al.  Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.

[19]  V. Ullrich,et al.  A new role for nicotine: selective inhibition of thromboxane formation by direct interaction with thromboxane synthase in human promyelocytic leukaemia cells differentiating into macrophages , 1992, The clinical investigator.

[20]  H. Schulman,et al.  Polyphenol tannic acid inhibits hydroxyl radical formation from Fenton reaction by complexing ferrous ions. , 1999, Biochimica et biophysica acta.

[21]  M. Nefzger,et al.  A retrospective study of smoking in Parkinson's disease. , 1968, American journal of epidemiology.

[22]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.

[23]  P. Crooks,et al.  Metabolites of nicotine in rat brain after peripheral nicotine administration. Cotinine, nornicotine, and norcotinine. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[24]  H. Mcardle,et al.  Effect of nicotine on transferrin binding and iron uptake by cultured rat placenta , 1988, Journal of cellular physiology.

[25]  K. Fuxe,et al.  Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel- and diencephalon of the rat , 1998, Neuroscience.

[26]  E. Mendez-Alvarez,et al.  Reduction of rat brain levels of the endogenous dopaminergic proneurotoxins 1,2,3,4-tetrahydroisoquinoline and 1,2,3,4-tetrahydro-β-carboline by cigarette smoke , 2001, Neuroscience Letters.

[27]  K. Yagi,et al.  Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. , 1979, Analytical biochemistry.

[28]  F. Dajas,et al.  Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra 1 1 Published on the World Wide Web on 1 December 2000. , 2001, Brain Research.

[29]  B. Halliwell,et al.  Oxygen toxicity, oxygen radicals, transition metals and disease. , 1984, The Biochemical journal.

[30]  C. Mytilineou,et al.  Destruction of sympathetic nerve terminals by 6-hydroxydopamine: protection by 1-phenyl-3-(2-thiazolyl)-2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n-butanol. , 1976, The Journal of pharmacology and experimental therapeutics.

[31]  K. Fuxe,et al.  Chronic continuous infusion of (−)nicotine reduces basic fibroblast growth factor messenger RNA levels in the ventral midbrain of the intact but not of the 6-hydroxydopamine-lesioned rat , 1996, Neuroscience.

[32]  J. Greenfield,et al.  THE BRAIN-STEM LESIONS IN PARKINSONISM , 1953, Journal of neurology, neurosurgery, and psychiatry.

[33]  R. Soto-Otero,et al.  Studies on the interaction between 1,2,3,4-tetrahydro-β-carboline and cigarette smoke: a potential mechanism of neuroprotection for Parkinson's disease , 1998, Brain Research.

[34]  M. Youdim,et al.  Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. , 1995, European journal of pharmacology.

[35]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[36]  J. Obeso,et al.  Dopamine Cell Degeneration Induced by Intraventricular Administration of 6-Hydroxydopamine in the Rat: Similarities with Cell Loss in Parkinson's Disease , 2001, Experimental Neurology.

[37]  B. Steinmann,et al.  Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. , 1974, Journal of chromatography.

[38]  D. Morens,et al.  Cigarette smoking and protection from Parkinson's disease , 1995, Neurology.

[39]  Yves Agid,et al.  Parkinson's disease: pathophysiology , 1991, The Lancet.

[40]  R. Andrew,et al.  The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controls , 1993, Neurochemical Research.

[41]  W. H. Oertel,et al.  Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.

[42]  C. Olanow,et al.  Neurodegeneration and Neuroprotection in Parkinson's Disease , 1996 .

[43]  D. Armstrong,et al.  Comparison of Pure Nicotine- and Smokeless Tobacco Extract-Induced Toxicities and Oxidative Stress , 1999, Archives of environmental contamination and toxicology.

[44]  E. Mendez-Alvarez,et al.  In vitro inhibition of catalase activity by cigarette smoke: relevance for oxidative stress , 1998, Journal of applied toxicology : JAT.

[45]  F. Vaglini,et al.  Nicotine Prevents Experimental Parkinsonism in Rodents and Induces Striatal Increase of Neurotrophic Factors , 1998, Journal of neurochemistry.

[46]  C. Olanow,et al.  Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders , 1996 .

[47]  A. Seidler,et al.  Smoking and Parkinson's disease: a case-control study in Germany. , 1997, International journal of epidemiology.

[48]  E Méndez-Alvarez,et al.  Inhibition of brain monoamine oxidase by adducts of 1,2,3,4-tetrahydroisoquinoline with components of cigarette smoke. , 1997, Life Science.

[49]  A. Schapira,et al.  Free radicals and mitochondrial dysfunction in Parkinson's disease. , 1993, Biochemical Society transactions.

[50]  A. Davison,et al.  Intermediates in the aerobic autoxidation of 6-hydroxydopamine: relative importance under different reaction conditions. , 1989, Free radical biology & medicine.

[51]  T. Miller,et al.  Terephthalic acid: a dosimeter for the detection of hydroxyl radicals in vitro. , 1994, Life sciences.

[52]  Y. Funae,et al.  Role of human cytochrome P4502A6 in C-oxidation of nicotine. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[53]  G. Wetscher,et al.  Free radical production in nicotine treated pancreatic tissue. , 1995, Free radical biology & medicine.

[54]  W. Oertel,et al.  Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.

[55]  S. Harik,et al.  Nicotine Enhances 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Neurotoxicity , 1992, Journal of Neurochemistry.

[56]  J. Baron,et al.  Cigarette smoking and Parkinson's disease , 1986, Neurology.

[57]  E Méndez-Alvarez,et al.  Interaction of 1,2,3,4-tetrahydroisoquinoline with some components of cigarette smoke: potential implications for Parkinson's Disease. , 1996, Biochemical and biophysical research communications.

[58]  W. Linert,et al.  In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's diseases. , 1999, Biochimica et biophysica acta.

[59]  J. Cadet,et al.  Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence , 1989, Brain Research.

[60]  D. Berg,et al.  Brain iron pathways and their relevance to Parkinson's disease , 2001 .

[61]  D. Togasaki,et al.  Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamine , 1995, Neuroscience.